Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...8889909192939495969798...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Cetuximab associated dermal filler reaction. (Pubmed Central) -  Feb 8, 2020   
    He developed significant inflammation around the dermal filler sites after first cycle of cetuximab which improved with dissolution of the dermal fillers with hyaluronidase. This suggests that cetuximab can lead to inflammation around the dermal filler sites, which can be treated with dissolution of the filler.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Cetuximab-Associated Pneumatosis Intestinalis. (Pubmed Central) -  Feb 7, 2020   
    Altogether, our findings indicate that TGF-beta-activated CAFs play a role in limiting cetuximab efficacy in HNC. No abstract available
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) -  Jan 31, 2020   
    P1,  N=28, Recruiting, 
    Repeated HPP treatments with mitomycin C plus cisplatin, followed by cetuximab targeted-therapy, may represent a safe and efficacious palliative therapy in patients with unresectable recurrent rectal cancer, in progression following standard systemic chemo- and radio-therapy, and thus warrants confirmation in a larger phase III study. Trial completion date: Apr 2020 --> Apr 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
  • ||||||||||  Trial primary completion date, Combination therapy:  Bevacizumab in Multiple Phase I Combinations (clinicaltrials.gov) -  Jan 30, 2020   
    P1,  N=354, Active, not recruiting, 
    Trial completion date: Apr 2020 --> Apr 2021 | Trial primary completion date: Apr 2020 --> Apr 2021 Trial primary completion date: Oct 2019 --> Oct 2020
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Ratiometric bioluminescent sensor proteins based on intramolecular split luciferase complementation. (Pubmed Central) -  Jan 29, 2020   
    The new sensor design also improved the dynamic response of a sensor for the therapeutic antibody cetuximab 4-fold, allowing the direct quantification of this anti-EGFR antibody in undiluted blood plasma. The modular sensor architecture allows easy and systematic tuning of a sensor's dynamic range and should be generally applicable to allow rational engineering of bioluminescent sensor proteins.
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases:  SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) -  Jan 27, 2020   
    P3,  N=400, Recruiting, 
    The therapeutic sequence of regorafenib followed by cetuximab suggests a longer OS than the current standard sequence. Not yet recruiting --> Recruiting | Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Feb 2021 --> Feb 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Drivers of Secondary Resistance to Anti-Egfr Therapy in Metastatic Colorectal Cancer (atrium) -  Jan 25, 2020 - Abstract #DKK2020DKK_2417;    
    Taken together, these results support a role of IGF2 and FGFs as candidate proteins conferring SR in an autocrine fashion in the setting of KRAS wild-type mCRC under chronic anti-EGFR treatment. Importantly, these results also suggest that potential combination therapies of Cmab and an IGF2 or FGF inhibitor could prevent establishment of SR and offer new treatment opportunities for patients with SR mCRC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Case of Two Patients with MSI-High Metastatic Colorectal Cancer Treated with Pembrolizumab (Room A2) -  Jan 25, 2020 - Abstract #DKK2020DKK_2050;    
    Therefore, we emphasize the importance of testing for MSI. Further clinical studies are needed in order to verify efficacy and safety of ICI in mCRC patients and to identify those patients with MSI-high mCRC that do not benefit from ICI therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Cetuximab and Radiation Therapy in Head and Neck Cancer. (Pubmed Central) -  Jan 24, 2020   
    Despite lack of significant OS increase, taxane based TPEx regimen appears to be a new option in 1st line R/M HNSSCC, with a shorter time on CT and significantly lower toxicity than the EXTREME regimen. No abstract available
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Enrollment change, Trial withdrawal, Metastases:  AlloStim (clinicaltrials.gov) -  Jan 22, 2020   
    P2/3,  N=0, Withdrawn, 
    Not yet recruiting --> Recruiting N=450 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  napabucasin (BBI608) / Sumitomo Pharma
    Trial completion, Metastases:  A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) -  Jan 22, 2020   
    P2,  N=203, Completed, 
    N=450 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Review, Journal:  Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. (Pubmed Central) -  Jan 21, 2020   
    Intriguingly, these subclonal events largely seem to converge on RAS/RAF/MAPK pathway in patients treated with EGFR-targeted monoclonal antibodies. This review describes the clinical and biological evolution and development of EGFR targeted therapies in mCRC, the challenges in the presence of molecular complexities, the role of cell free (cf)-DNA and future strategies that could lead to further optimal discovery of clinically meaningful biomarkers and application of precision medicine.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial primary completion date, Surgery:  Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) -  Jan 21, 2020   
    P2,  N=59, Active, not recruiting, 
    This review describes the clinical and biological evolution and development of EGFR targeted therapies in mCRC, the challenges in the presence of molecular complexities, the role of cell free (cf)-DNA and future strategies that could lead to further optimal discovery of clinically meaningful biomarkers and application of precision medicine. Trial primary completion date: Dec 2019 --> Mar 2020
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Clinical, Review, Journal:  MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. (Pubmed Central) -  Jan 19, 2020   
    In this study, we review the mechanisms of tumor cell resistance to mAb therapies and the role of miRNAs therein. Emerging treatment strategies combine therapies using innovative miRNA mimics or antagonizers with conventional approaches to maximize outcomes of patients with cancer.